Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMMETRY: Elesclomol + Paclitaxel in Metastatic Melanoma
NCT00522834Phase 3Terminated
- Sponsor
- Synta Pharmaceuticals Corp.
- Start
- Aug 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of elesclomol in melanoma, sponsored by Synta Pharmaceuticals Corp.. Started Aug 2007; status: terminated.
02
Drugs
elesclomol
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00522834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522834.